<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC2972676/results/search/test_trace/results.xml">
  <result pre="company committed to developing novel products for the prevention and" exact="treatment" post="of severe infectious diseases, with an emphasis on products"/>
  <result pre="the appropriate animal species and collecting enough natural history of" exact="infection" post="to support their use in regulatory applications. Also, the"/>
  <result pre="evolve resistance in the presence of antiviral drug selection. Thus," exact="treatment" post="for RNA pathogens may require combination of therapeutic modalities"/>
  <result pre="diseases such as the case of human immunodeficiency virus (HIV)" exact="treatment" post="or in the event that the drug had to"/>
  <result pre="of vaccines, antibiotics, and novel anti-infectives for the prevention and" exact="treatment" post="of severe infectious diseases for the past 10 years."/>
  <result pre="of our company, SIGA's drug development paradigm focuses on biological" exact="testing" post="prior to performing extensive medicinal chemistry. Many large pharmaceutical"/>
  <result pre="ICAR, Palm Springs, 2007). Therefore, with ST-246, one could initiate" exact="treatment" post="with the drug and then follow this with a"/>
  <result pre="a potential lead compound has been thoroughly evaluated before efficacy" exact="testing" post="begins. This means acceptable formulations, solubility, stability, and pharmacokinetic"/>
  <result pre="moving these types of antivirals through development, especially animal efficacy" exact="testing" post="(Fig. 2 ). We have set up essential collaborations"/>
  <result pre="anti-infectives against more traditional pathogens. References References QuenelleD.C.BullerR.M.ParkerS.KeithK.A.HrubyD.E.JordanR.KernE.R.Efficacy of delayed" exact="treatment" post="with ST-246 given orally against systemic orthopoxvirus infections in"/>
  <result pre="miceAntimicrob. Agents Chemother.51200768969517116683 SbranaE.JordanR.HrubyD.E.MateoR.I.XiaoS.Y.SiirinM.NewmanP.C.APD.A.R.TeshR.B.Efficacy of the antipoxvirus compound ST-246 for" exact="treatment" post="of severe orthopoxvirus infectionAm. J. Trop. Med. Hyg.76200776877317426185 YangG.PevearD.C.DaviesM.H.CollettM.S.BaileyT.RippenS.BaroneL.BurnsC.RhodesG.TohanS.HugginsJ.W.BakerR.O.BullerR.L.TouchetteE.WallerK.SchriewerJ.NeytsJ.DeClercqE.JonesK.HrubyD.JordanR.An"/>
 </snippets>
</snippetsTree>
